Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2017 Feb;17(1):60-64.
doi: 10.7861/clinmedicine.17-1-60.

ANCA-associated vasculitis

Max Yates  1 , Richard Watts  2
Affiliations
Review

ANCA-associated vasculitis

Max Yates et al. Clin Med (Lond). 2017 Feb.

Abstract

The vasculitides are a heterogeneous group of conditions typified by their ability to cause vessel inflammation with or without necrosis. They present with a wide variety of signs and symptoms and, if left untreated, carry a significant burden of mortality and morbidity. The antineutrophil cytoplasmic antibody (ANCA)-associated vasculitides (AAV) are three separate conditions - granulomatosis with polyangiitis (GPA; formerly known as Wegener's granulomatosis), microscopic polyangiitis (MPA), and eosinophilic granulomatosis with polyangiitis (EGPA; previously known as Churg-Strauss syndrome). This review examines recent developments in the pathogenesis and treatment of AAV, focusing on developments in treatment following the introduction of rituximab, in particular.

Keywords: ANCA; diagnosis; rituximab; treatment; vasculitis.

PubMed Disclaimer

Figures

Fig 1.
Fig 1.
Algorithm for treating ANCA-associated vasculitis. AAV = antineutrophil cytoplasmic antibody (ANCA)-associated vasculitides; AZA = azathioprine; CYC = cyclophosphamide; GC = glucocorticoids; MMF = mycophenolate mofetil; MTX = methotrexate; PLEX = plasma exchange; RTX = rituximab. Reproduced with permission from Ntatsaki et al.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Davies DJ. Moran JE. Niall JF. Ryan GB. Segmental necrotising glomerulonephritis with antineutrophil antibody: possible arbovirus aetiology? Br Med J. 1982;285:606. - PMC - PubMed
    1. Jennette JC. Falk RJ. Bacon PA, et al. Revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides. Arthritis Rheum. 2013;65:1–11. 2012. - PubMed
    1. Hilhorst M. van Passen Tervaert P. Limburg Renal Registry JW. Proteinase 3-ANCA vasculitis versus myeloperoxidase vasculitis. J Am Soc Nephrol. 2015;26:2314–27. - PMC - PubMed
    1. Watts RA. Mahr A. Mohammad AJ, et al. Classification, epidemiology and clinical subgrouping of antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis. Nephrol Dial Transplant. 2015;30(Suppl 1):i14–22. - PubMed
    1. Robson J. Doll H. Suppiah R, et al. Damage in the anca-associated vasculitides: long-term data from the European vasculitis study group (EUVAS) therapeutic trials. Ann Rheum Dis. 2015;74:177–84. - PubMed

MeSH terms